Gianluca Franceschini
Overview
Explore the profile of Gianluca Franceschini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
172
Citations
935
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kappos E, Haas Y, Schulz A, Peters F, Savanthrapadian S, Stoffel J, et al.
BMJ Open
. 2025 Feb;
15(2):e090662.
PMID: 39961719
Introduction: Up to one-fifth of breast cancer survivors will develop chronic breast cancer-related lymphoedema (BCRL). To date, complex physical decongestion therapy (CDT) is the gold standard of treatment. However, it...
2.
Mastrantoni L, Garufi G, Giordano G, Maliziola N, Di Monte E, Arcuri G, et al.
NPJ Breast Cancer
. 2025 Feb;
11(1):11.
PMID: 39910103
Hormone receptor-positive/HER2-negative breast cancer (BC) is the most common subtype of BC and typically occurs as an early, operable disease. In patients receiving neoadjuvant chemotherapy (NACT), pathological complete response (pCR)...
3.
DArchi S, Carnassale B, Sanchez A, Accetta C, Belli P, De Lauretis F, et al.
J Pers Med
. 2025 Jan;
15(1).
PMID: 39852228
B3 breast lesions, classified as lesions of uncertain malignant potential, present a significant diagnostic and therapeutic challenge due to their heterogeneous nature and variable risk of progression to malignancy. These...
4.
Fabi A, Rossi A, Caputo R, Pisegna S, Scagnoli S, Pantano F, et al.
NPJ Precis Oncol
. 2025 Jan;
9(1):22.
PMID: 39843642
Tumor dissemination to the central nervous system (CNS) is almost a rule in the treatment journey of advanced HER2+ breast cancer (BC). Recent results demonstrated high intracranial efficacy with Trastuzumab...
5.
Franceschini G, DArchi S, Di Leone A, Masetti R
Updates Surg
. 2025 Jan;
PMID: 39831929
No abstract available.
6.
Franceschini G
Expert Rev Anticancer Ther
. 2025 Jan;
25(2):189-190.
PMID: 39814682
No abstract available.
7.
DArchi S, Carnassale B, Accetta C, Belli P, De Lauretis F, Di Guglielmo E, et al.
J Clin Med
. 2025 Jan;
14(1.
PMID: 39797153
: B3 breast lesions, characterized by uncertain malignant potential, pose a significant challenge for clinicians. With the increasing use of preoperative biopsies, there is a need for careful management strategies,...
8.
Franceschini G
Clin Exp Med
. 2025 Jan;
25(1):26.
PMID: 39751921
The study titled "Primary tumor surgery in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium" opens an important discussion about the potential role...
9.
Franceschini G, Masetti R
Eur J Surg Oncol
. 2024 Dec;
51(2):109505.
PMID: 39637739
No abstract available.
10.
Barone Adesi L, Taraschi F, Macri G, Scardina L, Di Leone A, Franceschini G, et al.
J Clin Med
. 2024 Sep;
13(17).
PMID: 39274192
Breast cancer treatment increasingly incorporates immediate prepectoral prosthetic reconstruction after conservative mastectomy, including nipple-sparing (NSMs) and skin-sparing mastectomies (SSMs). Although recent data from the literature show that postmastectomy radiotherapy (PMRT)...